These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 17360759

  • 1. Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.
    Muzammil S, Armstrong AA, Kang LW, Jakalian A, Bonneau PR, Schmelmer V, Amzel LM, Freire E.
    J Virol; 2007 May; 81(10):5144-54. PubMed ID: 17360759
    [Abstract] [Full Text] [Related]

  • 2. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.
    Norelli S, El Daker S, D'Ostilio D, Mele F, Mancini F, Taglia F, Ruggieri A, Ciccozzi M, Cauda R, Ciervo A, Barreca ML, Pistello M, Bendinelli M, Savarino A.
    Curr HIV Res; 2008 Jun; 6(4):306-17. PubMed ID: 18691029
    [Abstract] [Full Text] [Related]

  • 3. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S, Kang LW, Velazquez-Campoy A, Kiso Y, Amzel LM, Freire E.
    Proteins; 2004 May 15; 55(3):594-602. PubMed ID: 15103623
    [Abstract] [Full Text] [Related]

  • 4. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
    Ohtaka H, Schön A, Freire E.
    Biochemistry; 2003 Nov 25; 42(46):13659-66. PubMed ID: 14622012
    [Abstract] [Full Text] [Related]

  • 5. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.
    Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley MG.
    Antiviral Res; 2005 Oct 25; 68(1):27-35. PubMed ID: 16122817
    [Abstract] [Full Text] [Related]

  • 6. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
    Ohtaka H, Velázquez-Campoy A, Xie D, Freire E.
    Protein Sci; 2002 Aug 25; 11(8):1908-16. PubMed ID: 12142445
    [Abstract] [Full Text] [Related]

  • 7. Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations.
    Tzoupis H, Leonis G, Avramopoulos A, Mavromoustakos T, Papadopoulos MG.
    J Phys Chem B; 2014 Aug 14; 118(32):9538-52. PubMed ID: 25036111
    [Abstract] [Full Text] [Related]

  • 8. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.
    Baxter JD, Schapiro JM, Boucher CA, Kohlbrenner VM, Hall DB, Scherer JR, Mayers DL.
    J Virol; 2006 Nov 14; 80(21):10794-801. PubMed ID: 16928764
    [Abstract] [Full Text] [Related]

  • 9. Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant.
    Todd MJ, Luque I, Velázquez-Campoy A, Freire E.
    Biochemistry; 2000 Oct 03; 39(39):11876-83. PubMed ID: 11009599
    [Abstract] [Full Text] [Related]

  • 10. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S, Ross P, Freire E.
    Biochemistry; 2003 Jan 28; 42(3):631-8. PubMed ID: 12534275
    [Abstract] [Full Text] [Related]

  • 11. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
    Leonis G, Steinbrecher T, Papadopoulos MG.
    J Chem Inf Model; 2013 Aug 26; 53(8):2141-53. PubMed ID: 23834142
    [Abstract] [Full Text] [Related]

  • 12. Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.
    de Mendoza C, Morelló J, Garcia-Gascó P, Rodríguez-Novoa S, Soriano V.
    Expert Opin Pharmacother; 2007 Apr 26; 8(6):839-50. PubMed ID: 17425479
    [Abstract] [Full Text] [Related]

  • 13. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.
    Naeger LK, Struble KA.
    AIDS; 2007 Jan 11; 21(2):179-85. PubMed ID: 17197808
    [Abstract] [Full Text] [Related]

  • 14. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
    Ntemgwa M, Brenner BG, Oliveira M, Moisi D, Wainberg MA.
    Antimicrob Agents Chemother; 2007 Feb 11; 51(2):604-10. PubMed ID: 17116674
    [Abstract] [Full Text] [Related]

  • 15. X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir.
    Klei HE, Kish K, Lin PF, Guo Q, Friborg J, Rose RE, Zhang Y, Goldfarb V, Langley DR, Wittekind M, Sheriff S.
    J Virol; 2007 Sep 11; 81(17):9525-35. PubMed ID: 17537865
    [Abstract] [Full Text] [Related]

  • 16. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class.
    Turner SR, Strohbach JW, Tommasi RA, Aristoff PA, Johnson PD, Skulnick HI, Dolak LA, Seest EP, Tomich PK, Bohanon MJ, Horng MM, Lynn JC, Chong KT, Hinshaw RR, Watenpaugh KD, Janakiraman MN, Thaisrivongs S.
    J Med Chem; 1998 Aug 27; 41(18):3467-76. PubMed ID: 9719600
    [Abstract] [Full Text] [Related]

  • 17. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.
    Rusconi S, La Seta Catamancio S, Citterio P, Kurtagic S, Violin M, Balotta C, Moroni M, Galli M, d'Arminio-Monforte A.
    Antimicrob Agents Chemother; 2000 May 27; 44(5):1328-32. PubMed ID: 10770770
    [Abstract] [Full Text] [Related]

  • 18. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
    Gupta A, Jamal S, Goyal S, Jain R, Wahi D, Grover A.
    BMC Bioinformatics; 2015 May 27; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
    [Abstract] [Full Text] [Related]

  • 19. Some insights into mechanism for binding and drug resistance of wild type and I50V V82A and I84V mutations in HIV-1 protease with GRL-98065 inhibitor from molecular dynamic simulations.
    Hu GD, Zhu T, Zhang SL, Wang D, Zhang QG.
    Eur J Med Chem; 2010 Jan 27; 45(1):227-35. PubMed ID: 19910081
    [Abstract] [Full Text] [Related]

  • 20. The higher barrier of darunavir and tipranavir resistance for HIV-1 protease.
    Wang Y, Liu Z, Brunzelle JS, Kovari IA, Dewdney TG, Reiter SJ, Kovari LC.
    Biochem Biophys Res Commun; 2011 Sep 09; 412(4):737-42. PubMed ID: 21871444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.